Jul 3 |
Grifols shareholder Scranton inks debt deal for plasma unit
|
Jul 1 |
Grifols’ Biotest to achieve USD 1 billion in US sales of Yimmugo® over next seven years
|
Jun 27 |
Grifols Leads Three Stocks That May Be Priced Below Their Estimated True Value
|
Jun 18 |
Grifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier Group
|
Jun 17 |
Biotest wins FDA approval for plasma protein therapy
|
Jun 17 |
Grifols prepares for late-stage plans with plasma-derived medicines in 2024
|
Jun 17 |
Grifols’ Biotest receives FDA approval for innovative Yimmugo® immunoglobulin to treat primary immunodeficiencies
|
May 21 |
GigaGen doses first subject in Phase I advanced solid tumour trial
|
May 9 |
Short Seller Gains on Grifols Bet That Tripped Elliott Spinout
|
May 7 |
Grifols: Why To Watch From The Sidelines
|